Novo Nordisk researchers nominated for Europe's top innovation prize

Novo NordiskA team of researchers from Novo Nordisk is nominated for Europe's top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the European Patent Office and the European Commission.

Prizes will be awarded in four categories: industry, small- and medium-sized enterprises/research institutes, non-European countries and lifetime achievement. Novo Nordisk is nominated in the 'industry' category, competing against French aviation company Airbus and German automaker Audi.

The invention for which the Novo Nordisk researchers are nominated concerns Levemir® (insulin detemir), a long-acting modern insulin that covers the body's basal insulin need and which today is used by more than one million people with diabetes. They have been nominated for "significantly improving the safety and quality of life of diabetes patients with a new insulin derivative for once-daily administration".

"The patent describes a technology for prolonging the duration of action of insulin. The invention is pioneering a new generation of modified human peptide hormones, because the technology can be applied more broadly to optimise the therapeutic value of proteins, including insulin and GLP-1," explains Svend Havelund, one of the inventors.

This year's award ceremony will be held alongside the European Patent Forum 2008, 'Inventing a cleaner future', in Ljubljana. The awards will be presented by Danilo Türk, the president of the Republic of Slovenia, and Alison Brimelow, the president for the European Patent Office.

The prize recognises inventors and innovations that have made a significant and lasting contribution to technical development in Europe and beyond and thus have strengthened Europe's economic position. All the nominated projects were patented by the European Patent Office between 1993 and 2002.

The team of Novo Nordisk researchers are Svend Havelund, John Broberg Halstrom, Ib Jonassen, Asser Sloth Andersen and Jan Markussen.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

FDA approves first oral GLP-1 treatment for type 2…

The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along w...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...